Evidence map›Paper›PMID 41694398›Full record

ArticleFrontiers in immunology2026

Exosomal ANGPTL2 in cerebrospinal fluid as a novel prognostic biomarker for primary central nervous system lymphoma.

Lili Zhu, Qing Li, Jingjing Ma, Huiwen Xu, Yan Ma, Zhiguang Lin, Mengxue Zhang, Songmei Wang, Xuanyi Wang, Bobin Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lili Zhu *Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Qing Li *Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Jingjing MaDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Huiwen XuDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Yan MaDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Zhiguang LinDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Mengxue ZhangDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Songmei WangLaboratory of Medical Molecular Biology, Experimental Teaching Center, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xuanyi WangKey Laboratory of Medical Molecular Virology of the Ministry of Education and The Ministry of Health, School of Basic Medical Sciences, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
Bobin ChenDepartment of Hematology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Angiopoietin-like protein 2 (ANGPTL2) functions as a key pro-tumorigenic mediator in the tumor microenvironment. While liquid biopsies using exosomal proteins to reflect tumor phenotypes and progression are well established for extracranial cancers, their use in primary central nervous system lymphoma (PCNSL) remains unexplored. Therefore, this study aimed to assess the potential of exosomal ANGPTL2 in cerebrospinal fluid (CSF) as a prognostic biomarker for PCNSL. Methods: We retrospectively reviewed the medical records of patients newly diagnosed with PCNSL at our institution from May 2020 to September 2023. Using enzyme-linked immunosorbent assay (ELISA), we measured CSF exosomal ANGPTL2 levels in 78 patients with PCNSL. Patients were divided into high- and low-level groups based on the median. The Kaplan-Meier analysis with a log-rank test was used to compare survival rates between groups. Univariate analysis was used to identify prognostic factors, and multivariate Cox proportional hazards regression was used to determine the independent predictors of PCNSL outcomes. Results: The median level of CSF exosomal ANGPTL2 was 4.410 ng/mL. Patients with high CSF exosomal ANGPTL2 had significantly shorter progression-free survival (PFS; Conclusion: CSF exosomal ANGPTL2 is a novel, independent prognostic marker in PCNSL.

Indexed as

Angiopoietin-Like Protein 2Angiopoietin-like ProteinsBiomarkers, TumorCentral Nervous System NeoplasmsExosomesLymphomaAdultAgedFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesAngiopoietin-Like Protein 2Angiopoietin-like ProteinsANGPTL2 protein, humanBiomarkers, TumorANGPTL2cerebrospinal fluidexosomesprimary CNS lymphomaprognosis

Identifiers

PMID41694398
PMCPMC12894402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.